{
  "ticker": "OSL",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02967780",
  "id": "02967780",
  "pages": 8,
  "price_sensitive": false,
  "date": "20250709",
  "time": "1229",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250709/pdf/06lmwp44807g7h.pdf",
  "summary": "- **Announcement Type**: Update to previous announcement regarding SPP (Securities Purchase Plan)  \n- **Key Updates**:  \n  - Shareholder approval received at EGM (8 July 2025) for SPP shares and options.  \n  - Terms adjusted to reflect 1-for-400 share consolidation (approved 29 May 2025) and final SPP issue price (A$1.158 per share).  \n  - Maximum SPP shares to issue: **1,727,116**.  \n  - Attaching **options** (1:1 ratio) with exercise price A$0.003 (post-consolidation equivalent: A$1.20), expiring 31 July 2027.  \n  - SPP offer range: **A$2,000\u2013A$100,000** per eligible shareholder.  \n  - Funds raised for **clinical trials, working capital, and costs**.  \n\n- **Timetable**:  \n  - Record date: **23 May 2025** (passed).  \n  - SPP open: **4 June 2025**, closed: **4 July 2025**.  \n  - Results/issue date: **11 July 2025**.  \n\n- **Fees**:  \n  - Broker (Bell Potter Securities): **6% fee** on funds raised + **187,665 advisor options**.  \n  - Additional costs: **166,667 SPP shortfall commitment options**.  \n\n- **No underwriting or minimum subscription condition**.  \n\n*Omitted: Non-material legal/boilerplate details, director names, and routine operational updates.*",
  "usage": {
    "prompt_tokens": 3182,
    "completion_tokens": 334,
    "total_tokens": 3516,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-09T04:04:50.677223"
}